New Resource: Cancer Drug Pipeline Information for Patient Advocacy Groups

Patient advocacy groups will now benefit from a new, centralized source of information about cancer drug products or indications anticipated to enter the Canadian market.

The Cancer Drug Pipeline Information for Patient Advocacy Groups is a collaboration between the Canadian Cancer Action Network (CCAN) and the CADTH pan-Canadian Oncology Drug Review (pCODR). It is available now on the CCAN and CADTH websites.

“I’m very proud and excited to have been part of the collaborative process to create valuable resources to support patient advocacy groups. The Cancer Drug Pipeline Information for Patient Advocacy Groups will let patients have a peek into the future and learn what new cancer drugs could be coming over the next few years.”

- Dr. James (Jim) Gowing, Project Lead,
Health Technology Assessment File,
Canadian Cancer Action Network

This new resourceis intended to identify potential new cancer drug products or indications that could be submitted to pCODR in the near future. It will provide patient advocacy groups with longer lead times to prepare their pCODR submissions. The pipeline information is obtained from publicly available sources, including the US Food and Drug Administration.*

If you have any questions about the new Cancer Drug Pipeline Information for Patient Advocacy Groups, please contact CCAN at [email protected] or CADTH at [email protected].

* Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted to pCODR. The use of this information is solely intended to assist patient advocacy groups to be more informed about the anticipated cancer drug products or indications listed in the pipeline.